227 related articles for article (PubMed ID: 34399381)
41. Molecular characterization of carbapenem-resistant
Yan WJ; Jing N; Wang SM; Xu JH; Yuan YH; Zhang Q; Li AL; Chen LH; Zhang JF; Ma B; Ma Q; Li Y
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33587030
[No Abstract] [Full Text] [Related]
42. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
43. Mortality impact of empirical antimicrobial therapy in ESBL- and AmpC-producing Enterobacteriaceae bacteremia in an Australian tertiary hospital.
Lim CL; Spelman D
Infect Dis Health; 2019 Aug; 24(3):124-133. PubMed ID: 30928569
[TBL] [Abstract][Full Text] [Related]
44. In vivo study assessed meropenem and amikacin combination therapy against carbapenem-resistant and carbapenemase-producing Enterobacteriaceae strains.
Hagihara M; Kato H; Yamashita R; Soda M; Watanabe H; Sakanashi D; Shiota A; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Kitaichi K; Mikamo H
J Infect Chemother; 2020 Jan; 26(1):1-7. PubMed ID: 31735629
[TBL] [Abstract][Full Text] [Related]
45. Determining the Optimal Carbapenem MIC That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae.
Tamma PD; Huang Y; Opene BN; Simner PJ
Antimicrob Agents Chemother; 2016 Oct; 60(10):6425-9. PubMed ID: 27503655
[TBL] [Abstract][Full Text] [Related]
46. IMP-6 Carbapenemase-Producing Enterobacteriaceae Bacteremia Successfully Treated with Amikacin-Meropenem in Two Patients.
Nakakura I; Ogawa Y; Sakakura K; Imanishi K; Hirota K; Shimatani Y; Uehira T; Nakamori S; Sako R; Doi T; Yamazaki K
Pharmacotherapy; 2017 Oct; 37(10):e96-e102. PubMed ID: 28699652
[TBL] [Abstract][Full Text] [Related]
47. Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan.
Komatsu Y; Kasahara K; Inoue T; Lee ST; Muratani T; Yano H; Kirita T; Mikasa K
PLoS One; 2018; 13(8):e0202276. PubMed ID: 30157275
[TBL] [Abstract][Full Text] [Related]
48. Clinical Characteristics of and Risk Factors for Subsequent Carbapenemase-producing Enterobacterales (CPE) Bacteraemia in Rectal CPE Carriers.
Kang SW; Park S; Kim AR; Han J; Lee J; Seo H; Sung H; Kim MN; Chang E; Bae S; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Song EH; Chong YP
Int J Antimicrob Agents; 2023 Nov; 62(5):106959. PubMed ID: 37633425
[TBL] [Abstract][Full Text] [Related]
49. Clinical laboratory detection of carbapenem-resistant and carbapenemase-producing Enterobacteriaceae.
Miller S; Humphries RM
Expert Rev Anti Infect Ther; 2016 Aug; 14(8):705-17. PubMed ID: 27348447
[TBL] [Abstract][Full Text] [Related]
50. mCIM test as a reliable assay for the detection of CRE in the Gulf region.
Al Musawi S; Ur Rahman J; Aljaroodi SA; AlShammari L; Itbaileh A; Mohammed H; Saeed N; Abdalhamid B; Alkharsah KR; Aljindan RY
J Med Microbiol; 2021 Jul; 70(7):. PubMed ID: 34232118
[No Abstract] [Full Text] [Related]
51. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital.
Li C; Li Y; Zhao Z; Liu Q; Li B
J Infect Public Health; 2019; 12(1):26-31. PubMed ID: 30145151
[TBL] [Abstract][Full Text] [Related]
52. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia.
Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC
Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of a new selective agar medium for detection of carbapenem-resistant Enterobacteriaceae.
Kuwahara-Arai K; Morito A; Yanagisawa I; Hishinuma T; Mya S; Zan KN; Tohya M; Tada T; Tin HH; Sekiguchi JI; Watanabe S; Kirikae T
Diagn Microbiol Infect Dis; 2019 Dec; 95(4):114882. PubMed ID: 31495528
[TBL] [Abstract][Full Text] [Related]
54. Epidemiology of multidrug-resistant Enterobacteriaceae in Sri Lanka: First evidence of bla
Kumudunie WGM; Wijesooriya LI; Namalie KD; Sunil-Chandra NP; Wijayasinghe YS
J Infect Public Health; 2020 Sep; 13(9):1330-1335. PubMed ID: 32439355
[TBL] [Abstract][Full Text] [Related]
55. Precision medicine for the diagnosis and treatment of carbapenem-resistant Enterobacterales: time to think from a different perspective.
Reyes S; Nicolau DP
Expert Rev Anti Infect Ther; 2020 Aug; 18(8):721-740. PubMed ID: 32368940
[TBL] [Abstract][Full Text] [Related]
56. Clinical characteristics and outcomes of carbapenem-resistant Enterobacterales bacteremia in pediatric patients.
Liu YC; Lu CY; Yen TY; Chang LY; Chen JM; Lee PI; Huang LM
J Microbiol Immunol Infect; 2023 Feb; 56(1):84-92. PubMed ID: 36376217
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of the MBT STAR-Carba Assay for the Detection of Carbapenemase Production in
Cordovana M; Abdalla M; Ambretti S
Microb Drug Resist; 2020 Nov; 26(11):1298-1306. PubMed ID: 32412820
[TBL] [Abstract][Full Text] [Related]
58. Association Between Types of Carbapenemase and Clinical Outcomes of Infection Due to Carbapenem Resistance Enterobacterales.
Pudpong K; Pattharachayakul S; Santimaleeworagun W; Nwabor OF; Laohaprertthisan V; Hortiwakul T; Charernmak B; Chusri S
Infect Drug Resist; 2022; 15():3025-3037. PubMed ID: 35720254
[TBL] [Abstract][Full Text] [Related]
59. Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE).
Goodman KE; Simner PJ; Tamma PD; Milstone AM
Expert Rev Anti Infect Ther; 2016; 14(1):95-108. PubMed ID: 26535959
[TBL] [Abstract][Full Text] [Related]
60. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Mar; 58(10):256-60. PubMed ID: 19300408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
